Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.57 |
| ▸ | EGFR | P00533 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075952 | 1.00 | ERBB2 (0.57) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4073005 | 0.87 | ERBB2 (0.61) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4083330 | 0.87 | ERBB2 (0.76) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4083320 | 0.87 | ERBB2 (0.76) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL27709279 | 0.86 | ERBB2 (0.54) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL27699617 | 0.86 | ERBB2 (0.52) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4197751 | 0.85 | ERBB2 (0.69) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4074558 | 0.85 | ERBB2 (0.69) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4202156 | 0.85 | ERBB2 (0.54) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4189683 | 0.83 | ERBB2 (0.78) | ERBB2EGFRKCNH2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877397-B1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090023759-A1 | Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| CN-101208332-A | Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase | ASTRAZENECA AB (SE) | 2008-06-25 | — | — | CN | disclosed |
| EP-1877397-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117521-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023759-A1 | Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885KCNH2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.